Jerini Signs Collaboration Agreement with Baxter to Develop Peptide for Use in Therapeutic Protein Purification
Complete the form below to unlock access to ALL audio articles.
Jerini AG has announced the signing of a research collaboration agreement with Baxter AG to develop a novel synthetic molecule for use in affinity purification of a therapeutic protein.
Under the terms of the agreement, Jerini will use its Peptides-to-Drugs (P2D) technology platform to identify and develop a specific binding molecule for protein purification, which potentially offers key advantages over conventional antibody-assisted protein purification.
"We are very pleased to announce our fourth collaboration agreement with Baxter. Jerini's proprietary P2D technology platform offers a unique and highly effective approach in the development of novel peptidomimetics or small molecules with applications in protein purification as well as drug development," said Jens Schneider-Mergener, Chief Executive Officer at Jerini.
Under the terms of the agreement, Jerini will receive an upfront payment and full time equivalents (FTE) funding along with potential milestone payments for the achievement of discovery, preclinical, and clinical goals and royalties on eventual product sales.
